

17 February 2017

Our Ref: RFI 19452

Dear

**Freedom of Information Act 2000
COPD Medicines**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for the information relating to the above which you requested on 23 January 2017.

A response to each of the questions raised has been provided by the Woman and Acute Child Health Directorate and is attached in Appendix A.

Under the terms of the legislation, if you are unhappy with this response you have the right to seek a review within the Trust in the first instance. If you wish to do so, please write to me at the address below.

If after such a review you are still unhappy with the response, you have the right to appeal to the Information Commissioner who will undertake an independent review. The Information Commissioner can be contacted at The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, SK9 5AF.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

**L McAree (Miss)
Head of Information Governance &
Directorate Support**

We request information in relation to all the medicines listed below which are marketed for the treatment of chronic obstructive pulmonary disease:

- a) Anoro (vilanterol and umeclidinium) which is marketed by GlaxoSmithKline*
 - b) Braltus (tiotropium) which is marketed by Teva*
 - c) Duaklir (aclidinium bromide and formoterol fumarate dihydrate) which is marketed by Astra Zeneca*
 - d) Eklira (aclidinium) which is marketed by Astra Zeneca*
 - e) Incruse (umeclidinium) which is marketed by GlaxoSmithKline*
 - f) Seebri (glycopyrronium) which is marketed by Novartis*
 - g) Spiolto (tiotropium and olodaterol) which is marketed by Boehringer Ingelheim*
 - h) Spiriva (tiotropium) which is marketed by Boehringer Ingelheim*
 - i) Ultibro (indacaterol and glycopyrronium) which is marketed by Novartis or Pfizer*
- (the "COPD Medicines").*

In respect of each of the COPD Medicines, please could you provide us with the following information:

- Q1) A copy of any agreement relating to a rebate, discount, patient access, risk-sharing or other pricing scheme entered into by South Eastern HSC Trust in relation to the COPD Medicines which results in South Eastern HSC Trust paying less than the NHS list price for such COPD Medicines (whether by way of discount, rebate etc).*
- A1.* There are no agreements relating to a rebate, discount, patient access, risk sharing or other pricing schemes that have been entered into in relation to these products by the Trust. The items are available and procured regionally via the wholesaler framework agreement.
- Q2) A copy of any communications between South Eastern HSC Trust and the company or companies marketing such COPD Medicine in relation to such scheme*
- A2.* There are no such communications with the companies for these products from the Trust.
- Q3) Any information or requests sent to GP practices comprised within the CCG in the 6 months since contract signature with respect to such COPD Medicines schemes*
- A3.* No information or requests have been sent to GP practices in relation to these products by the Trust. This information would be sent by the Health and Social Care Board.